When to Outsource Peptide Synthesis: A Stage-Gated Model

What Samsung’s Move Signals for Peptide Developers

Samsung Biologics’ acquisition attempt is not a story about scale. PolyPeptide, with its dedicated SPPS infrastructure, modification expertise, and established GLP-1 synthesis capabilities, brings something a biologics CDMO cannot simply replicate by reassigning bioreactor capacity: a production chemistry platform that is native to peptides, not retrofitted to them.

This distinction matters to the peptide outsourcing decision because it points to a structural fact about the contract services landscape. Not all CDMOs carry equivalent capability at the peptide level. Public CapEx disclosures from large peptide CDMOs — including Bachem’s and PolyPeptide’s published capital programs, which run at roughly 15–27% of revenue — show that capacity expansions are primarily targeting high-volume GLP-1 analogs and other commercial-stage molecules, not the custom, modification-heavy sequences that dominate discovery and IND-enabling work. For development teams operating below Phase 3, the relevant supply question is often whether to stay internal, engage a specialist CRO/CDMO, or enter the queue at a mega-CDMO — and those three choices carry genuinely different risk and cost profiles.

The Four Decision Variables

Before reaching the stage gates, four variables must be characterized for your specific program. They are not equally weighted at all stages, but each one can shift which outsourcing mode is appropriate.

Molecule complexity encompasses sequence length, the presence of non-natural amino acids, hydrophobic or aggregation-prone stretches, cyclization (head-to-tail, sidechain-to-sidechain), disulfide bond topology, lipidation, PEGylation, isotope labeling, and conjugation. Standard linear peptides below 15 residues with canonical amino acids sit at the low end of synthesis risk. Long-chain sequences above 30 residues, multi-site modification, or simultaneous cyclization and conjugation sit at the high end.

Sintésis péptida Batch volume requirements are the most quantitatively tractable variable. Milligram quantities serve in vitro screening and initial SAR work. Single-gram batches typically support early in vivo proof-of-concept studies. Tens to hundreds of grams cover toxicology, IND-enabling, and Phase 1 supply. Kilogram and multi-kilogram volumes define Phase 2/3 and early commercial territory. Ton-scale production characterizes mature commercial pipelines.

Analytical obligations range from research-use-only characterization (HPLC purity, ESI-MS confirmation) to GMP-release testing packages (RP-HPLC, HRMS or MALDI-TOF, amino acid analysis, endotoxin by LAL, sterility testing, lot-specific CoA). Regulatory filings add method development, method validation, and a documented audit trail for every analytical run.

Commercialization goals determine your time horizon and the quality-system investment required now. A research asset being de-risked for early-stage fundraising has different requirements than a molecule entering IND-enabling studies or a compound on the path to a Phase 3 NDA/BLA filing. Decisions that are appropriate for a discovery asset can become regulatory liabilities if carried forward into a clinical program.

A note on what is established vs. what is our framework. The individual variables above — complexity drivers, volume-to-phase mapping, and analytical package expectations — reflect broadly established CMC practice and can be verified against regulatory guidance and independent CDMO sourcing literature. The specific numeric thresholds and the three-gate model that follows are our synthesis, offered as a planning heuristic rather than a regulatory standard. Treat the numbers as starting points for your own program’s assessment, not as fixed rules.

Gate 1: Internal Synthesis — The Conditions That Make It Defensible

Internal synthesis is not the default it once was. Establishing in-house peptide chemistry infrastructure requires capital investment in the range of $25–$40 million for a mid-scale GMP-capable facility, and that figure excludes ongoing costs for talent, compliance infrastructure, analytical equipment maintenance, and QA/QC systems. A higher-end commercial-scale GMP peptide plant can exceed $50 million — CordenPharma’s Swiss greenfield facility, for instance, was reported at over €500 million — which is one reason “build it ourselves” is so rarely the right default. According to PeptideStaff’s cost-benefit analysis of peptide outsourcing versus in-house production, outsourcing is typically more cost-effective at annual production volumes below 50 kg, and the in-house break-even point most commonly falls between 5 kg and 20 kg per year — a threshold that shifts higher as sequence complexity increases, because complex molecules demand more synthesis attempts, purification cycles, and analytical runs per gram of final product.

Internal synthesis becomes defensible when three conditions converge simultaneously:

The sequence family is routine and repeatable. If your program synthesizes a stable, well-characterized family of linear or simple cyclic peptides using canonical amino acids, and the synthesis route has been validated and repeated without unexpected failure modes, an internal platform can capture economies of repetition that an external vendor cannot offer at the same turnaround speed.

Your team already has the chemistry expertise, analytical infrastructure, and quality systems in place. The cost calculation changes entirely if the capital is already deployed. An existing internal platform that meets purity specifications (HPLC ≥ 95% for research, ≥ 98% for clinical-grade material) and runs a compliant analytical workflow already carries its fixed costs. The marginal cost per gram for familiar sequences can then outperform outsourced pricing.

Annual demand is predictable and large enough to justify keeping capacity utilized. Idle capacity is a cost center. If your annual synthesis demand fluctuates between 2 kg and 20 kg depending on which programs are active, an internal facility is running at low utilization much of the time. At volumes consistently above 20 kg per year on sequences your team has proven, the math can favor internal production — but this is a threshold most mid-stage biotech programs do not reach until late in a single clinical program.

The clearest argument for retaining internal synthesis is IP sensitivity. For programs where the sequence itself is the competitive differentiator and any transfer to an external party creates IP exposure concerns, keeping synthesis internal during early discovery provides a defensible control point — provided the internal platform can actually execute the chemistry.

⚠️ Warning: The appeal of internal control should not be used to rationalize underqualified infrastructure. A synthesis failure at the IND-enabling stage caused by inadequate internal analytical capability or equipment limitations can cost far more in program delay than the cost of engaging a specialist external partner from the outset.

Gate 2: Specialist Peptide CRO — When Agility Beats Scale

For most programs during discovery, lead optimization, and the transition toward IND-enabling studies, a specialist peptide CRO or small-footprint CDMO is the appropriate outsourcing mode. This gate covers mg to multi-kg quantities, research-grade to GMP-enabling analytical packages, and molecules from moderately complex to highly complex.

The case for a specialist partner at this stage rests on three distinct capability advantages.

Access to modification scope that internal labs cannot maintain. Complex modifications — non-natural amino acid incorporation, 300+ functional group libraries, multi-site cyclization, isotope labeling for DIKE studies, lipidation for GLP-1 analogs — require a specialist chemistry team that works these modifications repeatedly. The synthesis failure rate for aggregation-prone or disulfide-rich sequences drops substantially when the executing chemist has addressed that specific modification class dozens of times, not for the first time.

Sterility and analytical rigor without the GMP footprint investment. Research-grade material destined for cell-based or in vivo studies often requires contamination controls that go beyond standard fume-hood synthesis. A partner operating Class 100 cleanroom environments with validated endotoxin testing (LAL assay) and sterility controls produces material that can support pre-clinical studies directly, without the regulatory risk of contaminated batches invalidating costly animal studies. Independent CDMO sourcing guides note that specialist platforms maintaining ultra-sterile manufacturing alongside scalable synthesis lines can support programs from milligram-scale exploratory work through pilot-scale batches — with turnaround speeds that a large CDMO’s intake queue typically cannot match.

Process flexibility for iterative programs. Discovery chemistry requires iteration. A CRO that can turn around a panel of 20 sequence variants with HPLC/MS data within 2–3 weeks offers a fundamentally different value proposition than a large CDMO running a 12–18 month intake queue for new project starts. According to PeptideStaff’s mid-2026 US peptide CDMO capacity outlook, established US peptide CDMO facilities were operating at 78–85% utilization in mid-2026, with new-program lead times stretched to 9–15 months from contract execution (up from 6–9 months in 2023), and Tier 1 commercial-scale capacity extending to 18–24 months. At that utilization level, large CDMOs are optimizing for throughput on validated, volume-intensive programs — not for discovery-phase agility.

A worked example from the bench

Consider a representative scenario from our own project experience (details anonymized). A discovery-stage team brought us a 34-residue peptide with two disulfide bonds and a single non-natural amino acid — a class where their internal platform had already failed three synthesis attempts with unresolved impurity profiles. Rather than run a fourth internal campaign, we approached it as a modification-class problem: we screened two alternative protecting-group strategies and one on-resin cyclization route before committing to scale-up. The first successful milligram batch solved the aggregation issue, and the process was then validated through 5-gram and 25-gram pilot batches with HPLC purity above 98% and full ESI-MS confirmation.

The lesson was not that internal teams cannot solve hard sequences — it was that the cost of iterating on an unfamiliar modification class internally was three failed campaigns before the transfer decision was made. Had the team engaged a specialist at the first failure rather than the third, the discovery timeline would have compressed by roughly two months. This is the pattern behind Gate 1 to Gate 2 transition timing: the signal to move is the presence of an unvalidated modification class, not the count of failed attempts.

The primary limitation of Gate 2 partners, meanwhile, is the ceiling they carry into clinical territory. A specialist CRO may not have the validated commercial-scale infrastructure, the regulatory inspection history, or the multi-ton synthesis capacity required to serve as the primary CMO for a Phase 3 filing. Programs that progress through IND and into mid-stage clinical trials need to plan the tech transfer to a larger platform — ideally before Phase 2, not after Phase 3 enrollment has started.

Gate 3: Integrated CDMO — When the Program Outgrows the Specialist

The transition into Gate 3 territory is driven primarily by two signals: the need for GMP-grade material under validated manufacturing conditions, and the volume requirements that exceed what a specialist partner can serve with supply continuity guarantees.

Integrated large CDMOs bring five capabilities that matter exclusively in late-stage and commercial territory:

Validated GMP manufacturing lines with a regulatory inspection history (FDA, EMA, or both). This is a non-negotiable input for Phase 3 supply and NDA/BLA submission. A CDMO’s inspection record — including 483 observations and response quality — is a due diligence item, not a background check.

Process development to commercial transition in a single partner. Tech transfer between two different organizations at the Phase 2/3 boundary creates risk: any meaningful difference in process parameters, raw material sourcing, or equipment geometry can introduce lot-to-lot variability that requires re-characterization. An integrated CDMO that runs process development, scale-up, and commercial production as a single workflow eliminates that transfer risk.

Multi-ton synthesis capacity and supply continuity commitments. Commercial GLP-1 programs illustrate the volume requirements: announced peptide CDMO investments crossed $2.4 billion year-to-date in 2026, yet lead times for large-scale SPPS capacity additions remain 18–36 months. Programs entering Phase 3 should be contracting with partners whose stated commercial capacity exceeds their projected peak demand by a meaningful margin.

Regulatory documentation packages for major filing markets. A large CDMO maintaining DMFs (Drug Master Files) in the US, CTDs in Europe, and parallel submissions in APAC markets provides a documentation infrastructure that a specialist CRO was not designed to carry.

Financial stability and business continuity guarantees. The risk of a specialist partner ceasing operations mid-program is real — the Peptide Sciences shutdown in 2025 illustrated the supply chain disruption that vendor discontinuity creates. Large integrated CDMOs with diversified client portfolios and publicly audited financials carry lower business continuity risk for programs with long development timelines.

The cost of accessing Gate 3 capability, however, is not merely financial. Large CDMOs require longer contracting timelines, impose more rigid change control protocols, and are less responsive to the iterative chemistry adjustments that a development-stage molecule sometimes requires. Entering Gate 3 prematurely — before the molecule and process are sufficiently locked — creates a different class of risk than staying in Gate 2 too long.

Stage-Gated Decision Matrix

The following table summarizes which outsourcing mode is appropriate across the four decision variables and the relevant development stage.

The Transitions That Trip Programs Up

Each gate transition carries a distinct failure mode worth anticipating.

Internal to Gate 2 (moving from in-house to specialist CRO): The most common mistake is waiting until synthesis failures or purity shortfalls accumulate before making the call. Internal teams often invest additional synthesis cycles in a molecule that a specialist partner would have solved faster on the first attempt. The trigger for Gate 2 engagement should be the presence of a modification class, sequence length, or purification challenge that your internal team has not previously validated — not the number of failed attempts.

Gate 2 to Gate 3 (moving from specialist to integrated CDMO): Programs frequently enter this transition under-prepared. The specialist partner’s process has not been formally optimized for scale, the analytical methods have not been validated, and the tech transfer package does not yet exist. Starting a large CDMO engagement six months before Phase 3 supply is needed is generally too late given current queue lengths. The realistic planning horizon for initiating a Gate 3 partnership, including process transfer and validation batches, is 12–18 months before first Phase 3 patient dosing.

Bypassing Gate 2 (going from internal directly to integrated CDMO): Programs that attempt to transfer an underdeveloped process directly into a large CDMO’s GMP environment often encounter unexpected complications — yield drops, impurity profiles that differ from bench scale, sterility failures — at the worst possible time. The specialist CRO stage is not merely a cost-saving step; it is the process optimization stage that makes a GMP tech transfer succeed.

Questions to Ask Before You Commit to Any Outsourcing Mode

Regardless of which gate your program is entering, the following questions should be answered before a vendor agreement is signed.

On synthesis capability: Can this partner provide documented examples of synthesizing sequences of comparable length, hydrophobicity, and modification type? What is their reported synthesis success rate for this modification class, and what does failure look like in their process?

On analytical depth: What is the standard analytical package included at the quoted scope? Does the CoA include batch-specific RP-HPLC chromatograms at 214 nm and 254 nm, ESI-MS or MALDI-TOF confirmation, and — where applicable — lot-specific endotoxin data? How is impurity identification handled when the chromatogram shows unexpected peaks?

On scale-up comparability: If you are engaging a Gate 2 partner for pilot-scale material with a view to eventual transfer, what process parameters and equipment geometry differences should be expected at the next scale? This question surfaces assumptions that are better addressed before the first batch than after a failed scale-up.

On regulatory documentation: What is the format and completeness of their DMF or technology transfer package? For IND-enabling studies, this question is about future optionality — if you need to transfer the process into a GMP facility, the documentation from your current partner determines how much validation work you inherit.

On business continuity: What is the partner’s financial structure, client concentration, and contingency arrangement if capacity becomes unavailable? A sole-source arrangement at the IND-enabling stage is an acceptable risk for many programs; at Phase 3 supply, it generally is not.

Pro Tip: Ask for the transfer package index before you ask for a quote. A vendor that cannot describe what they would hand over at tech transfer has not done this successfully before — or has not thought carefully about your program’s future requirements.

Applying the Framework to Your Program

The Samsung Biologics filing and the PolyPeptide acquisition are not coincidental events. They reflect a broader market reality: peptide synthesis expertise is a distinct capability set that does not transfer automatically from biologics manufacturing, and the financial markets are now pricing that specificity directly. For a development organization with a peptide in active research or transitioning toward the clinic, that same logic applies at the program level.

A stage-gated peptide outsourcing decision is not a one-time procurement choice. It is a sequence of deliberate handoffs, each timed to the molecule’s actual development readiness rather than to administrative convenience or cost pressure. The teams that execute these handoffs well — with clean tech transfer documentation, early vendor qualification, and process lock before GMP entry — spend less time recovering from avoidable complications at later stages.

About MOL Changes (Promotional Section)

The section below describes our services and is separate from the educational framework above.

If your program sits at the Gate 2 boundary — complex modifications, mg to multi-kg scale, pre-IND or IND-enabling stage — and you are assessing which specialist partners have the modification scope, sterility controls, and scalability to bridge that window, MOL Changes’ peptide synthesis and CRO services cover custom sequence design, 300+ functional group modifications, Kelas 100 cleanroom sterile manufacturing, and scalable production from milligrams to kilograms under full HPLC/MS analytical verification. A technical feasibility assessment for your specific sequence and modification requirements is available as a starting point.

The decision about where to manufacture your peptide is ultimately a decision about where the expertise that your molecule requires actually resides. On that question, the $262 million disclosure from Samsung Biologics provides a clear data point: even at industrial scale, that expertise is not generic.

Last reviewed: September 13, 2026. This article reflects market data available as of that date; CDMO capacity, lead times, and pricing are moving targets and readers should verify current figures directly with vendors.

Sources referenced in this article include public deal disclosures (FiercePharma, DCAT/VCi), independent peptide CDMO sourcing analyses (PeptideStaff, CDMOHub, Biotech Research), and published CDMO capital-expenditure reports (Bachem, PolyPeptide). A full list of linked sources appears inline above.

Corrections and questions: contact the MOL Changes technical team — if any figure in this article is found to be inaccurate or out of date, we will update it and note the revision here.